Compare GSK plc (GSK) vs ServiceNow Inc (NOW) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

ServiceNow (NOW) trades at $104.85, down 5.76% over the past day, with a neutral technical signal. The stock shows strong fundamentals, with revenue growing from $7.2B in 2022 to $13.3B in 2025 and a robust gross profit margin of 76.56%. Recent earnings have mostly beaten expectations, and the company maintains positive operating cash flow. Analyst sentiment is overwhelmingly bullish, with an 85.51% buy rating and a consensus price target of $137.52, suggesting significant upside potential from current levels.

The outlook for NOW is positive, driven by its leadership in enterprise AI solutions and consistent financial performance. Investment opportunities include exposure to high-growth AI markets and strong cash generation. Key risks involve elevated valuation multiples, competitive pressures in the SaaS sector, and execution challenges in sustaining growth. The stock presents a compelling case for growth-oriented investors, though its high P/E ratio warrants caution amid market volatility.